ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
Status:
Unknown status
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the
etiology of the disease is not clearly understood, no specific therapeutic strategies was
defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of
disease progression, but the use of steroid was restricted because of its side effects.
However, there is no evidence from RCT on the question of whether combined use of steroid
with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore
undertook a randomized, multicenter study to investigate the efficacy and safety profile of
combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of
patients with IgAN.